CRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well.
As you might know, Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ) just kicked off its latest quarterly results...
The S&P 500 was quiet again, but Toast led several new buys. Robinhood and Arm were big earnings movers late.